

Colette DeJong

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7426979/colette-dejong-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20
papers

529
citations

10
h-index

23
g-index

27
ext. papers

678
ext. citations

11.8
avg, IF

4.31
L-index

#	Paper	IF	Citations
20	Tenofovir-based PrEP for COVID-19: an untapped opportunity?. <i>Aids</i> , 2021 , 35, 1509-1511	3.5	4
19	Trends in the Use of Angiotensin-Converting Enzyme Inhibitor and Angiotensin-II Receptor Blocker Among United States Adults From 1999 to 2018. <i>Endocrine Practice</i> , 2021 , 27, 503-504	3.2	
18	Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e007521	5.8	2
17	Deferral of Care for Serious Non-COVID-19 Conditions: A Hidden Harm of COVID-19. <i>JAMA Internal Medicine</i> , 2021 , 181, 274	11.5	12
16	Patients' Compliance With Quarantine Requirements for Exposure or Potential Symptoms of COVID-19. <i>Hawaii Journal of Health & Social Welfare</i> , 2021 , 80, 276-282	0.6	
15	An Ethical Framework for Allocating Scarce Inpatient Medications for COVID-19 in the US. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 2367-2368	27.4	18
14	The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19-First, Do No Harm. <i>JAMA Internal Medicine</i> , 2020 , 180, 1118-1119	11.5	16
13	Disclosure of Article Funding and Conflicts of Interest in High-Impact Clinical Journals. <i>Journal of General Internal Medicine</i> , 2020 , 35, 1345-1347	4	
12	Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D. <i>JAMA Internal Medicine</i> , 2020 , 180, 1696-1699	11.5	5
11	Shining a Light on Industry Payments to Health Care Professionals Who Are Not Physicians. <i>JAMA Internal Medicine</i> , 2019 , 179, 1432-1433	11.5	1
10	Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D. <i>JAMA Cardiology</i> , 2019 , 4, 828-830	16.2	26
9	Electrocardiographic Harbingers of Ventricular Tachycardia Arrest-A Moment of Pause. <i>JAMA Internal Medicine</i> , 2019 , 179, 249-251	11.5	
8	Validation of Prediction Models for Critical Care Outcomes Using Natural Language Processing of Electronic Health Record Data. <i>JAMA Network Open</i> , 2018 , 1, e185097	10.4	41
7	Continuing Problems With Financial Conflicts of Interest and Clinical Practice Guidelines. <i>JAMA Internal Medicine</i> , 2018 , 178, 1715	11.5	6
6	Medicare Part D Plans' Coverage and Cost-Sharing for Acute Rescue and Preventive Inhalers for Chronic Obstructive Pulmonary Disease. <i>JAMA Internal Medicine</i> , 2017 , 177, 585-588	11.5	15
5	Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. <i>JAMA Internal Medicine</i> , 2016 , 176, 1114-1122	11.5	289
4	Important Distinctions Concerning Pharmaceutical Company-Sponsored Meals and Prescribing Patterns-Reply. <i>JAMA Internal Medicine</i> , 2016 , 176, 1881	11.5	

3	Variation in Quality of Urgent Health Care Provided During Commercial Virtual Visits. <i>JAMA Internal Medicine</i> , 2016 , 176, 635-42	11.5	45
2	Incorporating a New Technology While Doing No Harm, Virtually. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 2351-2	27.4	23
1	Websites that offer care over the Internet: is there an access quality tradeoff?. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1287-8	27.4	14